Literature DB >> 33944717

Parental access to hospitalised children during infectious disease pandemics such as COVID-19.

A Goga1, U Feucht, S Pillay, G Reubenson, P Jeena, S Mahdi, N T Mayet, S Velaphi, N McKerrow, L R Mathivha, N Makubalo, R J Green, G Gray.   

Abstract

The COVID-19 pandemic has resulted in many hospitals severely limiting or denying parents access to their hospitalised children. This article provides guidance for hospital managers, healthcare staff, district-level managers and provincial managers on parental access to hospitalised children during a pandemic such as COVID-19. It: (i) summarises legal and ethical issues around parental visitation rights; (ii) highlights four guiding principles; (iii) provides 10 practical recommendations to facilitate safe parental access to hospitalised children; (iv) highlights additional considerations if the mother is COVID-19-positive; and (v) provides considerations for fathers. In summary, it is a child's right to have access to his or her parents during hospitalisation, and parents should have access to their hospitalised children; during an infectious disease pandemic such as COVID-19, there is a responsibility to ensure that parental visitation is implemented in a reasonable and safe manner. Separation should only occur in exceptional circumstances, e.g. if adequate in-hospital facilities do not exist to jointly accommodate the parent/caregiver and the newborn/infant/child. Both parents should be allowed access to hospitalised children, under strict infection prevention and control (IPC) measures and with implementation of non-pharmaceutical interventions (NPIs), including handwashing/sanitisation, face masks and physical distancing. Newborns/infants and their parents/caregivers have a reasonably high likelihood of having similar COVID-19 status, and should be managed as a dyad rather than as individuals. Every hospital should provide lodger/boarder facilities for mothers who are COVID-19-positive, COVID-19-negative or persons under investigation (PUI), separately, with stringent IPC measures and NPIs. If facilities are limited, breastfeeding mothers should be prioritised, in the following order: (i) COVID-19-negative; (ii) COVID-19 PUI; and (iii) COVID-19-positive. Breastfeeding, or breastmilk feeding, should be promoted, supported and protected, and skin-to-skin care of newborns with the mother/caregiver (with IPC measures) should be discussed and practised as far as possible. Surgical masks should be provided to all parents/caregivers and replaced daily throughout the hospital stay. Parents should be referred to social services and local community resources to ensure that multidisciplinary support is provided. Hospitals should develop individual-level policies and share these with staff and parents. Additionally, hospitals should ideally track the effect of parental visitation rights on hospital-based COVID-19 outbreaks, the mental health of hospitalised children, and their rate of recovery.

Entities:  

Year:  2021        PMID: 33944717     DOI: 10.7196/SAMJ.2021.v111i2.15388

Source DB:  PubMed          Journal:  S Afr Med J


  2 in total

1.  It's made a really hard situation even more difficult: The impact of COVID-19 on families of children with chronic illness.

Authors:  Jordana McLoone; Claire E Wakefield; Glenn M Marshall; Kristine Pierce; Adam Jaffe; Ann Bye; Sean E Kennedy; Donna Drew; Raghu Lingam
Journal:  PLoS One       Date:  2022-09-01       Impact factor: 3.752

2.  Allowing access to parents/caregivers into COVID-19 hospitalization areas does not increase infections among health personnel in a pediatric hospital.

Authors:  Daniela De la Rosa-Zamboni; María José Adame-Vivanco; Mercedes Luque-Coqui; Carlos Mauricio Jaramillo-Esparza; Fernando Ortega-Riosvelasco; Irineo Reyna-Trinidad; Ana Carmen Guerrero-Díaz; Sergio Gabriel Ortega-Ruiz; Sergio Saldívar-Salazar; Mónica Villa-Guillen; Jaime Nieto-Zermeño; Sergio René Bonilla-Pellegrini; Lourdes María Del Carmen Jamaica Balderas
Journal:  Front Pediatr       Date:  2022-09-14       Impact factor: 3.569

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.